The company’s updated guidance for revenue includes approximately $10.5B in anticipated revenues for Comirnaty and Paxlovid, approximately $5B and $5.5B, respectively. Including the contribution from Seagen and excluding revenues from Comirnaty and Paxlovid, Pfizer (PFE) continues to expect full-year 2024 operational revenue growth of 9% to 11% compared to 2023 revenues; and this growth guidance takes into consideration the reduction of sales associated with the previously announced global withdrawal of Oxbryta.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Pfizer reports Q3 adjusted EPS $1.06, consensus 62c
- Pfizer raises FY24 adjusted EPS view to $2.75-$2.95 from $2.45-$2.65
- Pfizer sees ‘at least’ $4B by 2024-end from cost realignment program
- Notable companies reporting before tomorrow’s open
- Options Volatility and Implied Earnings Moves This Week, October 28 – November 01, 2024